This ‘Access Denied’ series explores a systemic lack of transparency within government decision making between pharmaceutical companies and their relations with the governments. Through legal and investigative research, the series uncovers how this opacity prevented public accountability and good governance which, we argue, contributed to the gross inequity we have seen in access to COVID-19 health technologies.

The focus of this report is on the impact of the pharmaceutical industry on the UK Government during the COVID-19 pandemic. The report explores the historic oversized influence of the pharmaceutical industry; Government decision-making in the pandemic and whether lessons are being learnt.

The report calls for reforms of the pharmaceutical system so that it puts lives before profits, and actions to tackle conflict of interests, lobbying and the revolving door between the UK Government and the pharmaceutical industry.

To read or download the report please click on the link below. We would like to thank The Joseph Rowntree Charitable Trust for making this research possible.

Access Denied: Impact of Big Pharma Influence on UK Government decision-making during the COVID-19 pandemic